Ecolab Inc 8-K, filed Mar 30, 2021
Ecolab Inc. (ECL)
About this 8-K
Ecolab Inc filed this 8-K on March 30, 2021.
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| | |||
(State or other jurisdiction | | (Commission | | (IRS Employer |
| | | ||
(Address of principal executive offices) | | | | (Zip Code) |
Registrant’s telephone number, including area code 1- | ||
(Not applicable)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading symbol(s) | | Name of each exchange on which registered |
| | |||
| | |||
| |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
Ecolab Inc. (“Ecolab” or the “Company”) is providing as an exhibit to this Current Report on Form 8-K a table (Exhibit 99.1) with supplemental unaudited reportable segment net sales and operating income information for the years ended December 31, 2020 and December 31, 2019 reflecting international operations at the fixed currency exchange rates established by Company management at the beginning of 2021. The exhibit also reflects immaterial changes to the Company’s segment reporting structure, including the movement of certain customers and cost allocations effective in the first quarter of 2021.
The Company is also providing a table (Exhibit 99.2) with supplemental unaudited reportable segment net sales and operating income information for each of the four quarters of 2020 and for the twelve months ended December 31, 2020, reflecting the changes noted above. Ecolab also will publish the attached exhibits on its website located at www.ecolab.com.
The financial information in the tables represents a supplemental presentation of certain of Ecolab’s 2020 and 2019 reportable segment information as explained in this Current Report on Form 8-K and is not intended to replace the presentation of such information in Ecolab’s Quarterly Reports on Form 10-Q filed with respect to the first, second and third quarters of 2020 and Ecolab’s Annual Reports on Form 10-K filed with respect to the fiscal years ended December 31, 2020 and December 31, 2019.
The information in this Current Report on Form 8-K, including the exhibits attached hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, except as shall be expressly set forth by specific reference in such a filing.
2
Item 9.01 Financial Statements and Exhibits.
(d) | Exhibits. |
The following exhibits are furnished pursuant to Item 2.02 of Form 8-K and should not be deemed to be “filed” under the Securities Exchange Act of 1934.
Exhibit No. | | Description | | Method Of Filing | |
| | | | | |
(99.1) | | Supplemental Reportable Segment Information and Non-GAAP Reconciliation (unaudited). | | Filed herewith electronically. | |
| | | | | |
(99.2) | | | Filed herewith electronically. | | |
| | | | | |
(104) | | Cover Page Interactive Data File. | | Embedded within the Inline XBRL document. | |
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ECOLAB INC. | |
| | |
| | |
Date: March 30, 2021 | By: | /s/ David F. Duvick |
| | David F. Duvick |
| | Assistant Secretary |
4
Exhibit 99.1
ECOLAB INC.
SUPPLEMENTAL REPORTABLE SEGMENT INFORMATION
AND NON-GAAP RECONCILIATION
(unaudited)
Year ended December 31 (millions) | | 2020 | | 2019 | ||||||||||||
| | | | | | Fixed | | | | | | | | Fixed | | |
| | | | | | Currency | | | | | | | | Currency | | |
| | Values at | | | | Rate | | Values at | | Values at | | | | Rate | | Values at |
| | 2020 Rates | | Other | | Change | | 2021 Rates | | 2020 Rates | | Other | | Change | | 2021 Rates |
Net Sales | | | | | | | | | | | | | | | | |
Global Industrial | | $5,959.9 | | ($3.7) | | $92.0 | | $6,048.2 | | $5,994.6 | | ($1.4) | | $94.7 | | $6,087.9 |
Global Institutional & Specialty | | 3,577.2 | | 9.3 | | 42.5 | | 3,629.0 | | 4,412.1 | | 14.6 | | 50.5 | | 4,477.2 |
Global Healthcare & Life Sciences | | 1,189.1 | | 3.7 | | 48.3 | | 1,241.1 | | 979.0 | | 1.4 | | 37.2 | | 1,017.6 |
Other | | 1,093.3 | | (9.3) | | 19.4 | | 1,103.4 | | 1,211.7 | | (14.6) | | 23.4 | | 1,220.5 |
Corporate | | 102.4 | | - | | (1.8) | | 100.6 | | - | | - | | - | | - |
Subtotal at fixed currency rates | | 11,921.9 | | - | | 200.4 | | 12,122.3 | | 12,597.4 | | - | | 205.8 | | 12,803.2 |
Effect of foreign currency translation | | (131.7) | | - | | (200.4) | | (332.1) | | (35.4) | | - | | (205.8) | | (241.2) |
Total reported GAAP net sales | | $11,790.2 | | $- | | $- | | $11,790.2 | | $12,562.0 | | $- | | $- | | $12,562.0 |
| | | | | | | | | | | | | | | | |
Operating Income | | | | | | | | | | | | | | | | |
Global Industrial | | $1,106.0 | | ($0.2) | | $17.3 | | $1,123.1 | | $902.7 | | $2.6 | | $16.0 | | $921.3 |
Global Institutional & Specialty | | 321.9 | | (0.3) | | 2.4 | | 324.0 | | 939.8 | | (0.3) | | 6.3 | | 945.8 |
Global Healthcare & Life Sciences | | 207.6 | | 0.7 | | 10.0 | | 218.3 | | 124.5 | | (1.3) | | 6.0 | | 129.2 |
Other | | 131.5 | | (0.2) | | 1.5 | | 132.8 | | 167.0 | | (1.0) | | 3.7 | | 169.7 |
Corporate | | (347.5) | | - | | (2.2) | | (349.7) | | (279.7) | | - | | (3.9) | | (283.6) |
Subtotal at fixed currency rates | | 1,419.5 | | - | | 29.0 | | 1,448.5 | | 1,854.3 | | - | | 28.1 | | 1,882.4 |
Effect of foreign currency translation | | (23.8) | | - | | (29.0) | | (52.8) | | (9.1) | | - | | (28.1) | | (37.2) |
Total reported GAAP operating income | | $1,395.7 | | $- | | $- | | $1,395.7 | | $1,845.2 | | $- | | $- | | $1,845.2 |
Notes:
We evaluate the performance of our non-U.S. dollar functional currency international operations based on fixed currency exchange rates, which eliminate the impact of exchange rate fluctuations on our international operations. Fixed currency amounts are updated annually at the beginning of each year based on translation into U.S. dollars at foreign currency exchange rates established by management, with all periods presented using such rates. The "Fixed Currency Rate Change” columns in the table above reflect international operations at fixed currency exchange rates established by management at the beginning of 2021, rather than the 2020 established rates. The difference between the fixed currency exchange rates and the actual currency exchange rates is reported within the "Effect of foreign currency translation" row in the table above.
The ”Other” columns in the table above reflect immaterial changes between reportable segments, including the movement of certain customers and cost allocations.
The above table includes financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (“GAAP”), including fixed currency sales and fixed currency operating income. We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results. These non-GAAP financial measures are not in accordance with, or an alternative to, GAAP and may be different from non-GAAP measures used by other companies. Investors should not rely on any single financial measure when evaluating our business. We recommend that investors view these measures in conjunction with the GAAP measures included in the table.
Exhibit 99.2
ECOLAB INC.
SUPPLEMENTAL REPORTABLE SEGMENT INFORMATION AND NON-GAAP RECONCILIATION
2020 REVISED SEGMENT DATA AT 2021 FIXED CURRENCY EXCHANGE RATES
(unaudited)
(millions) | | 2020 | ||||||||
| | First Quarter | | Second Quarter | | Third Quarter | | Fourth Quarter | | Twelve Months |
| | Ended | | Ended | | Ended | | Ended | | Ended |
| | March 31 | | June 30 | | September 30 | | December 31 | | December 31 |
Net Sales | | | | | | | | | | |
Global Industrial | | $1,465.0 | | $1,498.5 | | $1,512.9 | | $1,571.8 | | $6,048.2 |
Global Institutional & Specialty |
| 1,087.2 | | 733.0 | | 914.4 | | 894.4 | | 3,629.0 |
Global Healthcare & Life Sciences | | 256.8 | | 321.4 | | 335.1 | | 327.8 | | 1,241.1 |
Other |
| 279.6 | | 249.1 | | 288.7 | | 286.0 | | 1,103.4 |
Corporate | | - | | 12.3 | | 47.2 | | 41.1 | | 100.6 |
Subtotal at fixed currency rates |
| 3,088.6 | | 2,814.3 | | 3,098.3 | | 3,121.1 | | 12,122.3 |
Effect of foreign currency translation |
| (68.0) | | (128.6) | | (79.7) | | (55.8) | | (332.1) |
Total reported GAAP net sales |
| $3,020.6 | | $2,685.7 | | $3,018.6 | | $3,065.3 | | $11,790.2 |
|
| | | | | | | | | |
Operating Income | | | | | | | | | | |
Global Industrial | | $209.6 | | $287.8 | | $302.3 | | $323.4 | | $1,123.1 |
Global Institutional & Specialty |
| 183.7 | | (38.0) | | 83.7 | | 94.6 | | 324.0 |
Global Healthcare & Life Sciences | | 24.0 | | 69.0 | | 69.0 | | 56.3 | | 218.3 |
Other |
| 21.8 | | 20.8 | | 45.8 | | 44.4 | | 132.8 |
Corporate |
| (55.1) | | (128.1) | | (74.2) | | (92.3) | | (349.7) |
Subtotal at fixed currency rates |
| 384.0 | | 211.5 | | 426.6 | | 426.4 | | 1,448.5 |
Effect of foreign currency translation |
| (7.8) | | (19.5) | | (15.2) | | (10.3) | | (52.8) |
Total reported GAAP operating income |
| $376.2 | | $192.0 | | $411.4 | | $416.1 | | $1,395.7 |
Notes:
We evaluate the performance of our non-U.S. dollar functional currency international operations based on fixed currency exchange rates, which eliminate the impact of exchange rate fluctuations on our international operations. Fixed currency amounts are updated annually at the beginning of each year based on translation into U.S. dollars at foreign currency exchange rates established by management, with all periods presented using such rates. The difference between the fixed currency exchange rates and the actual currency exchange rates is reported within the "Effect of foreign currency translation" rows in the table above.
The table also reflects the other immaterial changes between reportable segments noted in Exhibit 99.1, including the movement of certain customers and cost allocations.
The above table includes financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (“GAAP”), including fixed currency sales and fixed currency operating income. We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results. These non-GAAP financial measures are not in accordance with, or an alternative to, GAAP and may be different from non-GAAP measures used by other companies. Investors should not rely on any single financial measure when evaluating our business. We recommend that investors view these measures in conjunction with the GAAP measures included in the table.